Genentech’s Divarasib Cuts Death Risk 44% Versus Standard Treatments in Phase III Lung Cancer Trial

By Public Technologies
  • Genentech’s investigational divarasib outperformed sotorasib or adagrasib in the Phase III Krascendo 1 trial in previously treated KRAS G12C-mutated non-small cell lung cancer.
  • Patients receiving divarasib lived longer and experienced delayed disease progression compared with those receiving the current treatments.
  • No new safety signals emerged; fewer patients stopped treatment because of treatment-related adverse events.
  • Results were presented at the 2026 ESMO Congress and simultaneously published in The New England Journal of Medicine.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genentech Inc. published the original content used to generate this news brief on October 25, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.